Complementary businesses combine to create a preeminent North American platform with operations spanning 13 wellness clinics, four research sites and one bioanalytical laboratory Shared mission of responsibly reintroducing psychedelic therapy to mental healthcare Hosting clinical trials for MDMA (MAPS Public Benefit Corporation), psilocybin (the Usona Institute), LSD (MindMed) and ketamine (the…


Previous articlePT308 – Dr. Ido Cohen, PsyD – Vital Psychedelic Conversations
Next articlePT309 – Jon Dennis, Esq. – Oregon’s Measure 109 and the Fight For Religious Liberty